By Lauren Taylor from In The Cloud Copy Onconova Therapeutics, Inc. is a biopharmaceutical company that works to develop new drugs to treat cancer, primarily focusing on myelodysplastic syndromes. Myelodysplastic…
Recently, biopharmaceutical company BerGenBio ASA ("BerGenBio") announced that their drug candidate bemcentinib reached its primary efficacy endpoint in a Phase 2 clinical trial. The drug is designed to treat patients…
A study conducted by researchers from the Institute of Cancer Research in London and Cyclacel has recently been published in PLOS ONE. This investigation examined fadraciclib as a potential therapy…
Results of a Phase III study of CC-486 (oral form of azacitidine) showed a significant improvement for older patients who had been transfusion dependent. The results were favorable when…
According to an article in Globe NewsWire, Onconova Therapeutics, a biopharmaceutical company currently focusing on myelodysplastic syndromes, recently announced results of its Phase 1 study of oral rigosertib in…
According to a story from GlobeNewswire, the biopharmaceutical company Onconova Therapeutics, Inc. has recently published results from a phase 1 clinical trial that was sponsored by the company. This trial…
After forty years of research to counter or cure acute myeloid leukemia and other blood cancers, a few years ago the medical community exploded with eight new cancer drugs.…
In a recent press release, the U.S. Food and Drug Administration (FDA) announced their approval of Inqovi for patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The…
COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…
Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…
Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…
Genetic research is a burgeoning and exciting field. With the discovery of new genetic mutations and variants comes a deeper understanding of rare diseases and their subtypes. According to Cancer…
A recent study published in Blood Cancer Journal has established a new method for effectively predicting survival outcomes for patients with low-risk myelodysplastic syndromes (MDS). The method is known as the…
A new study published in Blood has found different genetic variants of myelodysplastic syndromes (MDS). The most common of these is called SF3B1, which occurs in around 1 in every 5 patients. It…
According to a story from BioSpace, Acceleron Pharma Inc. and Bristol Myers Squibb have announced recently that the US Food and Drug Administration (FDA) has recently approved a new drug…
The Patient and Family/Caregiver Forum February 22nd, 2020 Houston, Texas This free MDS patient forum is geared towards MDS patients, their families, and caregivers. Learn critical information about MDS, its…
By Rachel Whetstone from In The Cloud Copy Many patients with myelodysplastic syndromes (MDS) are elderly when they’re diagnosed with the disease. Although stem cell transplants are often thought to…
One of our partner organizations, the MDS Foundation, is hosting another free MDS Patient & Family Forum in Chapel Hill, NC. When: September 26th Where: The Siena Hotel 1505 East Franklin Street…
According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…
The Patient and Family/Caregiver Forum February 1st, 2020 Birmingham, Alabama This free MDS patient forum is geared towards MDS patients, their families, and caregivers. Learn critical information about MDS, its…
The Platform Notable's automated technology platform was created to help predict which patients would respond better to which therapies. As no patient is the same, this study is paramount. Notable…
One of our partners, the MDS Foundation, Inc, is sponsoring another free MDS Patient & Family/Caregiver Forum. This event will be held in Birmingham, Alabama When: Saturday, February 1, 2020…
One of our partners, the MDS Foundation, Inc, is sponsoring another free MDS Patient & Family/Caregiver Forum. This event will be held in Houston, Texas When: Saturday, February 22, 2020 Where:…
TrialJectory is an organization working to match bladder, breast, colorectal, melanoma, myelodysplastic syndromes (MDS), and other cancer patients with the clinical trial that is right for them. They have successfully raised…
According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
